摘要
探讨血清人附睾分泌蛋白4(HE4)和CA125在监测老年卵巢癌转归中的价值。选取年龄大于60岁、经手术和病理证实的卵巢癌患者75例、盆腔良性疾病患者73例、其它恶性肿瘤患者53例和健康人103名,采集血清进行HE4和CA125测定,并对其中12例老年卵巢癌患者的血清HE4和CA125水平进行17～32个月的随访研究,研究HE4和CA125与病情发展的关系。结果显示:HE4检测老年性卵巢癌的特异性优于CA125;随着治疗进行,HE4水平随病情缓解而降低,术后HE4水平下降比CA125快;病情复发时CA125升高时间比HE4平均滞后3～6个月。HE4始终处于高水平的患者病情预后差。结论:HE4对老年卵巢癌检测特异性高,可用于监测治疗效果、预测病情复发和预后。
To evaluate the value of human epididymis secretory protein 4（HE4） and CA125 in monitoring recurrence and prognosis of ovarian cancer.All individuals enrolled in the test must be above 60.The serum HE4 and CA125 levels were determined in pathology proved ovarian cancer group（75 cases）,benign ovarian diseases group（73 cases）,other malignant tumor group（53 cases） and healthy women group（103 cases）.Follow-up studies were performed in 12 patients with ovarian cancer and the serum levels of HE4 and CA125 were detected.The results showed that the specificity of HE4 in the detection of elder ovarian cancer was higher than that of CA125.The serum HE4 level was decreased as the remission of the disease,and it decreased more quickly than that of serum CA125.In case of recurrence of the disease,the expression of serum CA125 delayed up to 3-6 months than that of HE4.The poorer prognosis was occurred in patients with a high serum HE4 level.The specificity of HE4 in the detection of ovarian cancer in elder women is satisfied and it may be acted as a good indicator for the remission,recurrence and prognosis of ovarian cancer.
出处
《标记免疫分析与临床》
CAS
2011年第6期374-379,共6页
Labeled Immunoassays and Clinical Medicine
